LipiFlow vs thermostatic devices
- no estimate extractedStudies not reportedLow
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether face‐down positioning changes proportion of eyes with retinal displacement at 6 months or later… compared with other positioning (very low certainty).
It is very uncertain whether face‐down positioning changes mean change in logMAR or Snellen visual acuity from baseline to 3… compared with other positioning (very low certainty).
It is very uncertain whether face‐down positioning changes mean objective distortion score at 3 months or later (lower is… compared with other positioning (very low certainty).
It is very uncertain whether face‐down positioning changes quality of life assessments at 3 months or later (higher is favored) compared with other positioning (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Sodium modelling changes adverse events compared with slow dialysis (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ High sodium dialysate changes dialysis dysequilibrium syndrome compared with standard sodium dialysate (very low certainty).
It is very uncertain whether summary of findings table ‐ High sodium dialysate changes severe dialysis dysequilibrium syndrome compared with standard sodium dialysate (very low certainty).
It is very uncertain whether summary of findings table ‐ High sodium dialysate changes adverse events compared with standard sodium dialysate (very low certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 3P‐MACE median compared with placebo (moderate certainty).
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 4P‐MACE median compared with placebo (moderate certainty).